OMERS Administration Corp’s Akebia Therapeutics AKBA Stock Holding History

OMERS Administration Corp’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-56,700	Closed	-$155K	–	1047
2025 Q3	$155K	Sell	56,700 -67,000	-54%	-$223K	﹤0.01%	1007
2025 Q2	$450K	Buy	+123,700	New	+$340K	﹤0.01%	665
2024 Q2	–	Sell	-77,000	Closed	-$141K	–	1035
2024 Q1	$141K	Buy	+77,000	New	+$123K	﹤0.01%	299
2018 Q4	–	Sell	-259,830	Closed	-$2.29M	–	151
2018 Q3	$2.29M	Buy	259,830 +204,030	+366%	+$1.82M	0.02%	229
2018 Q2	$557K	Buy	+55,800	New	+$559K	0.01%	300

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OMERS Administration Corp's AKBA Position: Q4 2025 in Review

OMERS Administration Corp sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 56,700 shares — an estimated $155K sold.

OMERS Administration Corp first reported a position in AKBA in Q2 2018 and held it in 5 quarters. The position peaked at $2.29M in Q3 2018. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

OMERS Administration Corp reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
OMERS Administration Corp sold 56,700 Akebia Therapeutics shares in Q4 2025, an estimated $155K.
OMERS Administration Corp first reported a position in Akebia Therapeutics in Q2 2018 and held it in 5 quarters.
OMERS Administration Corp's Akebia Therapeutics position peaked at $2.29M in Q3 2018.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on OMERS Administration Corp's 13F filing for Q4 2025, filed 13 Feb 2026.